LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$317.21M, compared with -$10.46M a year earlier.
Context
- Net debt amounted to 80.6% of total assets at the end of Q1 FY2026, up 26.3 pp from a year earlier.
- Net debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -2931.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (246.6M) USD
- Year-over-year change
- -1179.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (246.6M) | -1179.4% |
| FY2024 | 2024-12-31 | (19.28M) | -28.7% |
| FY2023 | 2023-12-31 | (14.98M) | -645.9% |
| FY2022 | 2022-12-31 | 2.74M | — |
Net Debt vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 net debt of -$317.21M is the 8th highest of the 10 companies compared; the peer median is -$204.49M.
- Its year-over-year change of -2931.4% is the 9th highest of 10, against a peer median of -83.9%.
- Net debt amounts to 80.6% of total assets for LBRX, versus a peer median of 25.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$50.12M | -14.5% | — | 12.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$67.25M | -35.1% | — | 13.5% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$146.66M | -16.5% | — | 95.3% |
| Jun 2026 | -$174.03M | -83.9% | — | 15.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | -$204.49M | -1101.1% | — | 19.0% |
| Mar 2026 | -$242.22M | +0.8% | — | 88.0% | |
| Mar 2026 | -$258.07M | -92.1% | — | 93.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$317.21M | -2931.4% | — | 80.6% |
| Sep 2026 | -$919.12M | -352.4% | — | 51.2% | |
| Jun 2026 | -$24.58B | -161104.7% | — | 25.8% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | -$204.49M | -83.9% | — | 25.8% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.